Currently, replication stress is recognized to play a prominent role in driving genomic instability and tumorigenesis, while further drug-mediated enhancement of replication stress or inhibition of replication stress-tolerance pathways such as ATR-Chk1 signaling may provide additional targetable vulnerabilities of cancer [13,14]. This evidence concerns the gene ATR and cancer.